CMS Targets Leadless Pacers For Medicare Coverage Analysis
This article was originally published in Clinica
Executive Summary
The Medicare agency signaled that it plans to establish a national coverage policy for leadless pacemakers in a memo issued May 18. The memo comes about one month after FDA approved the first such product, Medtronic’s Micra transcatheter leadless single-chamber pacemaker.
You may also be interested in...
Leadless Pacers Would Only Be Covered In Clinical Trials Under Medicare Proposal
The proposed national coverage policy, which was generated from an internal request by the US Medicare agency, would provide Medicare coverage of leadless pacemakers only if they are part of an FDA-approved trial that evaluates peri-procedural complications, post-procedural complications, long-term outcomes, and the influence of patient characteristics on outcomes.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.